Clinical trial
An Open-label, Multicenter Trial to Assess the Long-term Safety and Tolerability of ITI 1284 as Either Adjunctive or Monotherapy Treatment in Patients With Generalized Anxiety Disorder (GAD) With a History of Inadequate Response to GAD Treatment
NCT07807865 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Trial to Assess the Long-term Safety and Tolerability of ITI 1284 as Either Adjunctive or Monotherapy Treatment in Patients With Generalized Anxiety Disorder (GAD) With a History of Inadequate Response to GAD Treatment
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 3, 2026
- Completion date
- March 4, 2030
- Enrollment
- 900 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.